Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (ChiCTR2600131852) titled 'Clinical value of novel biomarker anti-BNLF2b antibody combined with EBV Rta-IgG and EBV VCA-IgA detection in early diagnosis of nasopharyngeal carcinoma patients' on Sept. 7.
Study Type: Observational study
Study Design:
Diagnostic test for accuracy
Primary Sponsor: The First People's Hospital of Foshan
Condition:
Nasopharyngeal carcinoma (NASopharyngeal carcinoma)
Intervention:
International Nasopharynx Cancer Study Group:None
Control group: outpatients with symptoms mimicking nasopharyngeal carcinoma (NPC), with nasopharyngeal carcinoma excluded.:None
Recruitment Status: Not Recruiting
Phase: N/A
...